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ABSTRACT
Introduction: it has been suggested that EGFR might be valua-
ble to select patients for immunotherapy for various types of cancers.
Aims: we investigated: a) the gene/proteins alterations in gas-
trointestinal cancers using immunohistochemistry (IHC) (gene ove-
rexpression) and fluorescence in situ hybridisation (FISH) (gene
amplification); and b) the associations between EGFR overexpres-
sion and amplification and chromosome 7 aneusomy (CEP7) in the-
se cancers.
Methods: 64 tumor specimens were evaluated by IHC and FISH:
17 adenocarcinoma arising in Barrett’s esophagus, 21 stomach can-
cers, 17 colon cancers, and 9 liver metastasis of colon carcinoma.
IHC for EGFR was scored at 4 levels of intensity of membrane stai-
ning. EGFR gene in FISH was considered as amplified or not and
chromosome 7 (where EGFR is located) as polisomic or disomic.
The ratio between EGFR gene and chromosome 7 was performed
by FISH and classified the case as gene amplification when the ratio
was > 2. Polisomy was identified when the copies of chromosome
7 were > 2 in more than 8% malignant cells.
Results: no difference was found between EGFR gene ampli-
fication/protein overexpression according to cancer site. Concer-
ning IHC, most cases were positive for EGFR intensity (84.4%),
while only 50% of cases were positive considering a cut-off of 10%.
EGFR FISH amplification was found in 4 cases only (6.2%) and
FISH CEP7 aneusomy in 40.6%. A statistically significant associa-
tion was found between EGFR protein positivity (IHC) in term of
intensity and EGFR gene amplification by FISH (p = 0.003), and
between the EGFR protein positivity (IHC) and chromosome 7 aneu-
somy (FISH) (p = 0.004).
Conclusions: EGFR amplification assessed by FISH was found
in only 4 cases (6.2%) while chromosome 7 aneusomy was identi-
fied in 26 (40.6%) cases. IHC proved that EGFR protein overex-
pression in gastrointestinal cancers is common but FISH assessment
showed that EGFR gene amplification is rare. An association was
observed between EGFR gene amplification and EGFR protein ove-
rexpression in a low number of cases (p = 0.003). A statistically sig-
nificant association was found between EGFR protein overexpres-
sion and chromosome7 polisomy (p = 0.004).
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INTRODUCTION
The epidermal growth factor receptor (EGFR) is a mem-
ber of the human epidermal growth factor receptors fami-
ly, which consists of four distinct members: HER1 or
EGFR, HER2 (also termed ErbB2 or HER2/neu), HER3
(also termed ErbB3), and HER4 (also termed ErbB4). These
receptors share the same molecular structure with an extra-
cellular, cystein-rich ligand-binding domain, a single alpha-
helix transmembrane domain, and an intracellular domain
with tyrosine kinase (TK) activity in the carboxy-termi-
nal tail (except HER3) (1).
Both EGFR and HER-2 receptors are targets for im-
munotherapy, and for this reason their protein expression
and gene amplification are widely investigated. In fact,
EGFR has been studied in a variety of pathological con-
ditions such as colorectal cancer, where it was identified
as a biomarker (2) and a target for immunotherapy (3), lung
cancer (4,5), liver metastasis from colonic carcinomas (6),
Barrett’s adenocarcinoma (7-9), pancreatic ductal adeno-
carcinoma (10), gastric cancer (11,12), head and neck squa-
mous cell carcinomas (13) and ovarian carcinomas (14).
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Under physiological conditions ligand binding is re-
quired to activate EGFR; however, in tumor cells there are
additional mechanisms of EGFR activation such as recep-
tor overexpression and autocrine production of ligands
by tumor cells (15,16).
EGFR overexpression has been associated with advanced
stages of disease, resistance to conventional treatments,
and poor prognosis (15,17). The anti-epidermal growth fac-
tor receptor (anti-EGFR) monoclonal antibodies cetuximab
and panitumumab seem to have a good clinical activity in
about 10% of patients with metastatic colorectal cancer
resistant to chemotherapy (3); however, the molecular
mechanism underlying clinical response or resistance to
these agent are still under investigation. Moreover, a stan-
dardized method of measurement and of patients’ selection
is not universally accepted at the moment.
Some authors have proposed that the response to anti-
EGFR treatment in colon and lung carcinomas has a genet-
ic background and suggested to select patients on the basis
of EGFR copy number (3,18), while others studies pro-
vided evidence that the presence of EGFR mutations –rather
than copy number– is more important in determining the
outcome with anti-EGFR therapy (4,19).
The aims of the present study were to investigate: a) the
gene/proteins alterations of cancers arising in Barrett’s esoph-
agus, stomach, colon, and of the liver metastasis of colon
cancer, by means of immunohistochemistry (IHC) and flu-
orescence in situ hybridisation (FISH); and b) the associa-
tion between EGFR overexpression and amplification and
chromosome 7 aneusomy in gastrointestinal cancers.
MATERIAL AND METHODS
Pathological evaluation
Immediately after sampling, all specimens were fixed
in 10% neutral-buffered formalin for 24 hours, then were
included in paraffin and stained with hematoxylin-eosin
(H&E) and Alcian-PAS for routine histological examina-
tion. H&E-stained slides from the resected specimens were
evaluated for identification of the steps in cancer progres-
sion. All the carcinomas were diagnosed according to the
WHO classification (20).
Sixty-four tumor specimens were evaluated: 17 adeno-
carcinomas arising in Barrett’s esophagus, 21 stomach can-
cers (6 diffuse type, 14 intestinal type, 1 intestinal type with
mucoid differentiation), 17 colon cancers (14 moderately-
poorly differentiated adenocarcinomas, 3 mucoid) and 9 liv-
er metastasis of colon carcinoma (2 cases were metastasis of
above colon cancer and 7 were from different cases).
Immunohistochemistry
EGFR (HER1) receptor status was analyzed by the EGFR
pharmDx kit (DAKOCytomation, Carpinteria, CA, USA).
According to the recommendations from the manufacturers,
tissue sections mounted on slides and stored at room temper-
ature (25 °C) were stained within 4-6 weeks from sectioning,
in order to maintain the antigenicity, and then the samples were
counterstained with Mayer’s hematoxylin. HER-1 oncopro-
tein expression was evaluated by two observers, following the
score system suggested by the manufacturer’s instruction.
Concerning EGFR assessment, this was considered posi-
tive when it primarily stained cell membrane, demonstrating
both complete and incomplete circumferential staining. The
immunostaining pattern was frequently heterogeneous,
exhibiting various staining intensities within a single neo-
plasm. Since there are no guidelines for scoring the samples,
in agreement with previous published studies (21,22) we cal-
culated a score based on the stain intensity of tumor cells: 0/1
(no or incomplete membrane staining); 2 (weak/ moderate
complete membrane staining); and 3 (strong and complete
membrane staining). Moreover, we considered the individ-
ual percentage of positive cells in each sample.
FIuorescence in situ hybridization (FISH)
EGFR is located on chromosome 7p12 and in FISH it is
investigated by a LSI© Locus Specific Identifier DNA Probe
labeled by Spectrum Orange fluorochrome (Vysis Inc., Down-
ers Grove, IL, USA). The LSI© probe consists of DNAprobe
sequences homologous to specific DNA regions. Gene
sequences or loci are directly labeled with one of the Vysis
fluorophores. Unlabeled blocking DNA is included with the
probe to suppress sequences contained within the loci which
are common to other chromosomes. When hybridized and
visualized, these probes show specific changes, such as ampli-
fication, deletion or translocation to specific gene, loci or chro-
mosomal regions. We analyzed also the centromeric region
of chromosome 7 (7p11.1-q11.1) with a Chromosome Enu-
meration Probe (CEP7) labeled by Spectrum Green fluo-
rochrome. The whole area of each neoplastic lesion present
in the tissue section was independently evaluated by two inves-
tigators (ER, VV) with a fluorescence microscopy (Nikon
Optiphot-2) equipped with selective filters for the fluo-
rochromes used, in high power fields (HPF; magnification
600x). FISH images were captured and elaborated using
Genikon software (Nikon Instruments S.p.A, Italy). The EGFR
gene locus was classified as amplified if there were more than
twice the number of red (Spectrum Orange labeling) EGFR
signals than green (Spectrum Green labeling) centromere
17 signals (ratio > 2:1) per cell nucleus, as previously described
(3). Polisomy was identified when the copies of chromosome
7 were more than 2 in more than 8% of malignant cells.
Reference values for abnormal FISH results were based
on criteria of Qian and colleagues for tissue sections, to
account for the potential artifacts due to nuclear overlap-
ping in fixed sections. According to these criteria an abnor-
mal autosomal gain required a minimum 8% nucleus with
three or more signals, whereas abnormal autosomal loss
required more than 55% nuclei with zero or one signal (23).
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Table I. Patient’s distribution and evaluation
# Sex Age Anatomic Diagnosis EGFR IHC EGFR EGFR EGFR Ratio Outcome
site intensity IHC % FISH CEP7 EGFR/CEP7 3 years
1 M 63 Esophagus ADC all thickness no LMN 1 5 NA Polisomy 1.2 Alive
2 M 70 Esophagus ADC all thickness no LMN 0 0 NA Disomy 1 Alive
3 F 65 Esophagus ADC all thickness 7 LMN 1 70 NA Polisomy 1.55 Alive
4 M 56 Esophagus ADC all thickness no LMN 0 0 NA Disomy 0.9 Alive
5 M 67 Esophagus ADC submucosa no LMN 2 65 NA Polisomy 1.68 NA
6 M 73 Esophagus ADC all thickness no LMN 3 96 A Polisomy 5.8 Died
7 M 64 Esophagus ADC all thickness no LMN 3 80 NA Disomy 1 Died
8 M 59 Esophagus ADC all thickness no LMN 3 80 NA Polisomy 1.9 Alive
9 M 74 Esophagus ADC all thickness no LMN 1 1 NA Polisomy 1.2 Alive
10 M 68 Esophagus ADC submucosa no LMN 0 0 NA Disomy 1 Alive
11 F 57 Esophagus ADC all thickness 4 LMN 1 1 NA Polisomy 1.35 Died
12 M 64 Esophagus ADC all thickness 2 LMN 3 80 NA Disomy 1 Died
13 M 69 Esophagus ADC all thickness no LMN 2 10 NA Disomy 1 Alive
14 M 63 Esophagus ADC all thickness no LMN 1 5 NA Disomy 0.83 Alive
15 M 68 Esophagus ADC submucosa no LMN 3 10 NA Disomy 1.01 Alive
16 M 71 Esophagus ADC submucosa no LMN 0 0 NA Disomy 0.91 Alive
17 M 60 Esophagus ADC all thickness 14 LMN 2 20 NA Disomy 1 Died
18 M 77 Stomach ADC early antrum 1 10 NA Disomy 1 Alive
19 M 54 Stomach ADC all thickness antrum no LNM 1 5 NA Disomy 1 NA
20 M 58 Stomach ADC all thickness antrum no LNM 3 20 NA Polisomy 1.55 NA
21 M 62 Stomach ADC all thickness corpus no LNM 2 60 NA Polisomy 1.63 Alive
22 F 66 Stomach ADC all thickness cardias 3 LNM 2 40 NA Disomy 0.99 NA
23 F 59 Stomach ADC all thickness cardias 5 LNM 1 5 NA Polisomy 1.74 Alive
24 M 69 Stomach ADC all thickness antrum no LNM 1 40 NA Disomy 1 Alive
25 F 70 Stomach ADC all thickness antrum no LNM 3 15 NA Polisomy 1.68 Alive
26 M 53 Stomach ADC all thickness corpus 2 LNM 3 10 NA Disomy 1 Alive
27 M 63 Stomach ADC all thickness cardias 5 LNM 0 0 NA Disomy 1 Alive
28 M 66 Stomach ADC all thickness cardias no LNM 1 2 NA Disomy 0.99 Alive
29 M 71 Stomach ADC all thickness antrum no LNM 2 60 NA Disomy 0.85 Alive
30 M 77 Stomach ADC all thickness antrum 2 LNM 2 90 NA Disomy 1 Died
31 M 65 Stomach ADC all thickness cardiac no LNM 1 5 NA Disomy 0.87 Alive
32 F 56 Stomach ADC mucoid all thickness antrum no LNM 3 90 A Polisomy 4 NA
33 M 63 Stomach Diffuse type corpus all thickness 5 LNM 1 5 NA Disomy 1 Alive
34 F 61 Stomach Diffuse type corpus early no LMN 3 10 NA Disomy 0.87 Died
35 F 74 Stomach Diffuse type angulus all thickness 15 LMN 1 30 NA Disomy 1 Died
36 M 64 Stomach Diffuse type corpus all thickness 6 LMN 1 5 NA Disomy 1 Died
37 M 46 Stomach Diffuse type corpus all thickness 12 LMN 3 50 NA Disomy 0.89 Died
38 F 42 Stomach Diffuse type antrum all thickness 5 LMN 0 0 NA Disomy 1 Alive
39 M 58 Colon ADC Dukes C 3 90 A Disomy 2.15 Alive
40 M 67 Colon ADC Dukes B 3 90 NA Polisomy 1.98 Alive
41 F 64 Colon ADC Dukes B 1 1 NA Polisomy 1.2 Alive
42 M 48 Colon ADC Dukes C 1 1 NA Polisomy 1.1 Alive
43 M 69 Colon ADC Dukes B 1 5 NA Polisomy 1.5 Alive
44 F 73 Colon ADC Dukes B 2 5 NA Disomy 1 Alive
45 F 75 Colon ADC Dukes C 0 0 NA Disomy 1 Alive
46 M 64 Colon ADC Dukes B 1 5 NA Polisomy 1.25 Alive
47* M 66 Colon* ADC* Dukes D 2 65 NA Disomy 1 Died
48* M 59 Colon* ADC* Dukes B 2 70 NA Disomy 0.9 Alive
49 M 71 Colon ADC Dukes B 3 80 NA Disomy 1 Alive
50 M 65 Colon ADC Dukes C 1 5 NA Disomy 0.98 Alive
51 M 69 Colon ADC Dukes C 1 10 NA Polisomy 1.58 Alive
52 M 57 Colon ADC Dukes B 3 10 A Polisomy 12 Alive
53 M 62 Colon ADC mucoid Dukes B 1 5 NA Polisomy 1.5 Alive
54 F 67 Colon ADC mucoid Dukes B 2 80 NA Polisomy 1.3 Alive
55 M 72 Colon ADC mucoid Dukes C 0 0 NA Disomy 0.88 Alive
56 M 71 Liver Metastasis of colon ADC 1 1 NA Polisomy 1.45 Died**
57 M 67 Liver Metastasis of colon ADC 0 0 NA Disomy 1 NA
58 F 58 Liver Metastasis of colon ADC 1 1 NA Polisomy 1.5 NA
59 M 48 Liver Metastasis of colon ADC 1 1 NA Polisomy 1.25 Died
60 M 64 Liver Metastasis of colon ADC 1 1 NA Polisomy 1.2 Alive**
61 M 66 Liver Metastasis of colon ADC 0 0 NA Disomy 0.9 NA
62 M 75 Liver Metastasis of colon ADC 1 1 NA Polisomy 1.8 NA
63* M 66 Liver* Metastasis of colon ADC* 1 10 NA Disomy 1 Died
64* M 59 Liver* Metastasis of colon ADC* 2 10 NA Disomy 0.9 Alive**
F: female; M: male; ADC: adenocarcinoma; FISH: fluorescence in situ hybridization; IHC: immunohistochemistry; A: amplified; NA: not amplified; CEP7: chromosome enumeration
probe for chromosome 7. *The cases analysed for the ADC in colon and its liver metastasis. **Treated with epidermal growth-factor receptor (EGFR) inhibitors cetuximab (Erbitux).
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Applying the same criteria used in the HER-2/neu eval-
uation (24,25), the cell population of each HPF was clas-
sified as displaying a disomy, an aneusomy (generally a
polisomy) or a gene amplification.
Statistical analysis
IHC was scored as 0,1,2, and 3 depending on intensity of
membrane staining, and categorized at 4 levels while the num-
ber of positive cells were indicated in percentage and dico-
tomized in < 10 (negative) and ≥ 10 (positive). FISH for
EGFR gene was considered positive when amplified and neg-
ative when not amplified. FISH for chromosome 7 was con-
sidered positive in presence of chromosome aneusomy (poli-
somy) and negative in presence of chromosome disomy.
The associations between EGFR protein intensity in IHC,
EGFR protein percentage of positivity in IHC, EGFR gene
in FISH, chromosome 7 aneusomy in FISH and the cancer
site, and the associations between EGFR gene amplifica-
tion and protein overexpression and chromosome 7 poli-
somy were evaluated using the usual statistical methods
for comparison of proportions. p-values lower than 0.05
(two-tailed tests) were used to reject the null hypothesis.
RESULTS
Overall, specimens from 64 patients were obtained. The
demographic characteristics, cancer anatomic site, histo-
logical diagnosis, and the results of EGFR gene amplifi-
cation, protein overexpression and the ratio EGFR/CEP7
are shown in table I. The mean age was 67.9 with a range
of 34-91 (SD: 11.7) years; most patients (78.1%) were
males. Patients with esophagus and stomach cancers were
older (mean ages: 73.1 and 70.4 years, respectively) than
those with colon cancer (mean age: 63.9 years) and with
liver metastasis (mean age: 59.4 years) (p = 0.008).
Most cases resulted positive when evaluating intensity
for EGFR by IHC (n = 54, 84.4%); in fact, only 10 cases
(15.8%) showed score 0, whereas by considering the per-
centage of positive cells ≥ 10%, 50% of cases resulted pos-
itive (Table II).
EGFR amplification visualized by FISH was found in
only 4 cases (6.2%) and chromosome 7 aneusomy was iden-
tified in 26 (40.6%) cases.
The distribution of gene amplification/protein overex-
pression/chromosome 7 aneusomy (polisomy) according to
cancer site are shown in table II. No statistically significant
difference was found in EGFR overexpression/amplification
and chromosome 7 polisomy according to cancer sites.
Representative images showing FISH and IHC for
EGFR in various cancer sites and histological subytpes are
shown in figures 1-3.
As summarised in table III, a statistically significant
association (p = 0.003) was found between EGFR protein
intensity score (3+) visualized by IHC and EGFR gene
amplification visualized by FISH.
Moreover, a statistically significant association was
found between EGFR protein overexpression and chro-
mosome 7 polisomy (p = 0.004).
Table III shows the association between EGFR gene
amplification by FISH and the number of positive cells
visualized by IHC; though not statistically significant, all
Table II. EGFR protein IHC intensity, EGFR protein IHC percentage, EGFR gene FISH evaluation,
chromosome 7 (CEP7) FISH evaluation according to anatomic site
Anatomic site
Esophagus cancer Stomach cancer Colon cancer Liver metastasis of Total
colon ADC
EGFR IHC intensity No. (%) No. (%) No. (%) No. (%)
0 4 (23.5) 2 (9.5) 2 (11.8) 2 (22.2) 10 (15.6)
1 5 (29.4) 9 (42.8) 7 (41.2) 6 (66.7) 27 (42.2)
2 3 (17.7) 4 (19.1) 4 (23.5) 1 (11.1) 12 (18.9)
3 5 (29.4) 6 (28.6) 4 (23.5) 0 (0) 15 (23.4)
EGFR %
≥ 10% 9 (52.9) 13 (61.9) 8 (47.1) 2 (22.2) 32 (50)
< 10% 8 (47.1) 8 (38.1) 9 (52.9) 7 (77.8) 32 (50)
EGFR FISH
A 1 (5.9) 1 (4.8) 2 (11.8) 0 4 (6.3)
NA 16 (94.1) 20 (95.2) 15 (88.2) 9 (100) 60 (93.7)
CEP7 FISH
Polisomy 7 (41.2) 5 (23.8) 9 (52.9) 5 (55.6) 26 (40.6)
Disomy 10 (58.8) 16 (76.2) 8 (47.1) 4 (44.4) 38 (59.4)
Total 17 (100) 21 (100) 17 (100) 9 (100) 64 (100)
FISH: fluorescence in situ hybridization; IHC: immunohistochemistry; A: amplified; NA: not amplified; CEP: chromosome enumeration probe.
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Fig. 1. Stomach cancer (case #32, table I) A. Hematoxylin and eosin stain.
B. IHC for EGFR shows a protein overexpression (brown stain). C. FISH
for EGFR (red spots) and chromosome 7 (green spots) shows a strong
gene amplification and clustering.
Fig. 2. IHC for EGFR. A. ADC arised in BE (case #12, table I) show a strong
protein overexpression (3+). B. Adenocarcinoma moderately differen-
tiated of the colon (case #40, table I) scored 2 + as intensity in IHC eva-
luation of EGFR. C. ADC in stomach cancer scored 3 + in the central area
which was only the 15% of the tumpur (case #25, table I). D. Negative
(0) stomach ADC (case #38, table I).
4 cases amplified by FISH showed ≥ 10% of malignant
cells by IHC positivity. No significant association was
found between EGFR IHC % positivity and chromosome
7 aneusomy. Three out 4 cases amplified by FISH (75%)
vs. 23 out 60 (38.3%) not amplified had chromosome7 poli-
somy (p > 0.05) (data not shown).
DISCUSSION
Anticancer drug discovery has shifted from an empiric
random screening approach to a more rational, target-direct-
ed approach. The use of small molecules with tyrosine
kinase inhibitory activity directed toward the EGFR, such
as gefitinib for non-small cell lung cancer (NSCLC) or
erlotinib for NSCLC and pancreas cancer, represent inter-
esting examples. However, these therapies have modest
activity when given to unselected patient populations.
One aim of this study was to investigate the EGFR gene
amplification/protein overexpression in gastrointestinal
tract cancer using both FISH and IHC techniques. We found
that most cases were positive for EGFR by IHC (54 out 64,
84.4%), whereas very few (4 out 64, 6.3%) showed EGFR
gene amplification.
We did not find any differences in the prevalence of
EGFR amplification/overexpression according to different
cancer sites and types, although the small number of
patients may be a limiting factor in our study. It is howev-
er worth noting the rarity of the EGFR gene amplification,
observed in 1 out 17 cases of ADC arising in BE, 1 out 21
cases of mucoid ADC of the stomach, and in 2 out 17 cas-
es of colon ADC. No liver metastasis of colon ADC were
found positive by IHC or FISH for EGFR, and this could
be due to number of the metastases analyzed or to a dif-
ferent behaviour of metastasis (cases # 63 and 64) com-
pared to primitive cancer (cases # 47 and 48).
It is well known how in other pathologies the absence
of gene amplification in cases which display a protein over-
expression could be due to a polisomy of the chromosome
where the gene is located. This is true, for example, in breast
cancer referred to HER-2 evaluation (26) where polisomy
of chromosome 17 plays an important rule.
We investigated the possible association between EGFR
and chromosome 7 polisomy, which is considered a mark-
er of tumor progression, often present in carcinomas (27).
Not surprisingly, we found an association between chro-
mosome 7 and EGFR gene overexpression evaluated by
IHC intensity. The association between chromosome 7
aneusomy and EGFR percentage of positive cells by IHC
was not statistically significant due to the small number of
amplified cases.
According to the DakoCytomation EGFR pharmDX kit
for EGFR testing a positive IHC stain for EGFR is defined
as ≥ 1% of tumor cells showing partial or circumferential
membrane staining of any intensity (above background),
but many authors suggest to consider the membrane inten-
sity with a score (0,1,2,3) and the percentage of positive
cells (21,22). We decided to consider these parameters sep-
arately and to investigate the possible associations between
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Fig. 3. FISH for EGFR. A. Gene amplification in colon cancer (case #52,
table I) as show the red spots (EGFR gene) spread in the nucleus. B. Poli-
somy for chromosome 7 (CEP7 green spots) in colon ADC (case #40,
table I). C. EGFR not amplified and without polisomy for chromosome
7 in ADC arising in BE (case #13, table I).
them. In our experience cases with only 1% cell positivi-
ty were not found. For this reason we decided to discrim-
inate as follows: positive > 10% and negative < 10%. Thus,
most cases resulted positive when evaluating intensity for
EGFR by IHC (n = 54, 84.4%), but if we consider the per-
centage of positive cells ≥ 10% only 50% of cases result-
ed positive (Table II), which would reduce dramatically the
potential patients suitable for therapy.
Among the cases amplified by FISH, though very few
(4 out 64), all of them showed the highest intensity by IHC
and more than 10% positive cells in EGFR IHC, and 3 of
them (75%) showed polisomy of chromosome 7.
Previous studies based on EGFR mutation, amplifica-
tion, overexpression showed that this gene modifies its
behavior depending on the tumors analyzed (3,4) and for
this reason there is no convincing and practical way to select
patients for the immunotherapy. Moreover, some authors
demonstrated that mutation of the KRAS oncogene is a
powerful negative predictive biomarker to identify patients
with metastatic colon cancer who do not benefit from
EGFR-I therapy (28). On the other hand, other authors
(3) argued that the confirmation of EGFR overexpression
by evaluating EGFR gene amplification by FISH may be
important to select patients for colon cancer treatment.
Some patients with high levels of EGFR expression are
refractory to EGFR inhibitor treatment, suggesting that
mere expression of EGFR is not a robust predictor of
response to therapy (29). The lack of a clear relationship
between the level of EGFR expression and the degree of
EGFR activation across tumor types complicates simple
prediction of clinical effectiveness of targeted therapeutic
approaches (30).
In conclusion, our study provides further data to the
debate regarding the evaluation of EGFR in the GI tract.
Even though we found a strong association between EGFR
gene/protein expression and chromosome 7 polisomy these
expressions seem to characterize only a small percentage
of GI carcinomas. This is the first report where GI tract
pathology has been analyzed with these techniques at the
same time within the different areas where the ADC arose
(esophagus, stomach, colon and liver metastasis). The rel-
atively low number of cases is due to the selection ADC
arising in the GI tract while avoiding the cases which
showed only dysplasia or dysplasia in the majority of the
tissue; thus, confirmation of these findings in a larger pop-
ulation could be intriguing.
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